

General information about company	
Name of The Company	MARKSANS PHARMA LIMITED
BSE Scrip Code	524404
NSE Symbol	MARKSANS
MSE Symbol	NA
Date of Start of Financial Year	01-04-2023
Date of End of Financial Year	31-03-2024
Reporting Period	Second half yearly
Date of Start of Reporting Period	01-10-2023
Date of End of Reporting Period	31-03-2024
Level of rounding to be used in disclosing related party transactions	Millions
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the banks/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	

Related party transactions

Related party transactions													Additional disclosure of related parties to loans, inter-company deposits, advances or investments. These details		
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness incurred to make or give loans, corporate deposits, advances or investments		
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost
1	Marksans Pharma Limited	AAACT3153G	Nova Pharmaceuticals Australasia Pty Ltd	ZZZZZ9999Z	Subsidiary	Sale of goods or services		1899.94	Nil	301.35	0	0			
2	Marksans Pharma Limited	AAACT3153G	Bell, Sons and Co. (Druggists) Limited	ZZZZZ9999Z	Step down Subsidiary	Sale of goods or services			Nil	331.77	0	0			
3	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Step down Subsidiary	Sale of goods or services			Nil	730.31	0	0			
4	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc	ZZZZZ9999Z	Step down Subsidiary	Sale of goods or services			Nil	2471.01	0	0			
5	Marksans Pharma Limited	AAACT3153G	Bell, Sons and Co. (Druggists) Limited	ZZZZZ9999Z	Step down Subsidiary	Sale of fixed assets			Nil	3.29	0	0			
6	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	REIMBURSEMENT OF EXPENSES		Nil	0.1	0	0			
7	Marksans Pharma Limited	AAACT3153G	Nova Pharmaceuticals Australasia Pty Ltd	ZZZZZ9999Z	Subsidiary	Any other transaction	Trade Receivable		Nil	0	350.18	495.86			
8	Marksans Pharma Limited	AAACT3153G	Bell, Sons and Co. (Druggists) Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Receivable		Nil	0	-62	-34.71			
9	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Receivable		Nil	0	-822.22	-861.98			
10	Marksans Pharma	AAACT3153G	Time-Cap Laboratories	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Receivable		Nil	0	2255.98	2629.15			

	Limited		Inc														
11	Marksans Pharma Limited	AAACT3153G	Bell, Sons and Co. (Druggists) Limited	ZZZZZ9999Z	Step down Subsidiary	Purchase of goods or services			Nil	0.87	0	0					
12	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Step down Subsidiary	Purchase of goods or services			Nil	0.85	0	0					
13	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc	ZZZZZ9999Z	Step down Subsidiary	Purchase of goods or services			Nil	0.48	0	0					
14	Marksans Pharma Limited	AAACT3153G	Bell, Sons and Co. (Druggists) Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Payable		Nil	0	0.89	0.43					
15	Marksans Pharma Limited	AAACT3153G	Relonchem Limited	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Payable		Nil	0	0.86	0.84					
16	Marksans Pharma Limited	AAACT3153G	Time-Cap Laboratories Inc	ZZZZZ9999Z	Step down Subsidiary	Any other transaction	Trade Payable		Nil	0	1.23	0.48					
17	Marksans Pharma Limited	AAACT3153G	Mark Saldanha	AHAPS0915M	Promoter & Key Managerial Personnel	Remuneration			Nil	40.59	0	0					
18	Marksans Pharma Limited	AAACT3153G	Sandra Saldanha	ALRPS8186P	Promoter & Key Managerial Personnel	Remuneration			Nil	3.54	0	0					
19	Marksans Pharma Limited	AAACT3153G	Jitendra Sharma	AJCPS5121K	Key Managerial Personnel	Remuneration			Nil	6.31	0	0					
20	Marksans Pharma Limited	AAACT3153G	Harshavardhan Panigrahi	AKTPP1644A	Key Managerial Personnel	Remuneration			Nil	1.5	0	0					
21	Marksans Pharma Limited	AAACT3153G	Varddhman Jain	ACWPJ0702A	Key Managerial Personnel	Remuneration			Nil	6.87	0	0					
22	Marksans Pharma Limited	AAACT3153G	Mark Saldanha	AHAPS0915M	Promoter & Key Managerial Personnel	Any other transaction	Rent Paid		Nil	5.33	0	0					
Total value of transaction during the reporting period										3904.17							

Text Block	
Textual Information(1)	
Textual Information(2)	
Textual Information(3)	
Textual Information(4)	
Textual Information(5)	
Textual Information(6)	
Textual Information(7)	
Textual Information(8)	
Textual Information(9)	
Textual Information(10)	
Textual Information(11)	
Textual Information(12)	
Textual Information(13)	
Textual Information(14)	
Textual Information(15)	
Textual Information(16)	
Textual Information(17)	Remuneration of Rs. 34.46 million is drawn from the Company and the remaining amount (Rs. 6.13 million) is the remuneration drawn from subsidiary Company.
Textual Information(18)	
Textual Information(19)	
Textual Information(20)	
Textual Information(21)	
Textual Information(22)	

